Victoria P. Werth, MD, and François Chasset, MD, PhD, discuss 52-week AMETHYST Part A data showing litifilimab responses continued to rise.
François Chasset, MD, PhD
Advertisement
Dermatology and Allergology Department, Faculty of Medicine, Tenon Hospital, and Sorbonne University, Paris, France.
Articles by François Chasset, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Tezepelumab Meets Co-Primary End Points in Phase 3 CROSSING Trial in EoE
2
Oral Icotrokinra Sustains UC Response Through 76 Weeks in ANTHEM-UC LTE
3
Guselkumab Sustains Histologic Healing in Ulcerative Colitis Over 3 Years
4
EADV Congress 2026: 5 Atopic Dermatitis Headlines to Know
5